By Karen Jagoda | Empowered Patient Podcast
Kura’s Executive Vice President of Clinical Development, Mollie Leoni, M.D., connected with Empowered Patient Podcast host, Karen Jagoda, to discuss the company’s ziftomenib program and the potential it holds for patients impacted by acute myeloid leukemia (AML).
Dr. Leoni emphasizes the critical need for new treatment options for AML patients, especially those with NPM1 mutations who have high response rates to frontline therapy, yet relapse rates are high and survival outcomes are poor. Menin inhibitors such as investigational drug candidate, ziftomenib, have the potential to address the significant unmet medical need within the AML patient population.
Listen to the full episode to learn more about the progress of Kura’s ongoing monotherapy and combination trials of ziftomenib following recent milestones including receiving FDA Breakthrough Therapy Designation for patients with relapsed/refractory (R/R) NPM1- AML and enrollment completion in the KOMET-001 monotherapy trial.
